Evidence map›Paper›PMID 40312476›Full record

ArticleScientific reports2025

Global burden of non-melanoma skin cancers among older adults: a comprehensive analysis using machine learning approaches.

Yumeng Pan, Bo Tang, Yingwu Guo, Yuzhou Cai, Yu-Ye Li

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Hydrogen Sulfide Metabolism in the Skin: From Physiology to Malignancy.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yumeng PanDepartment of Dermatology, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China.
Bo TangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yingwu GuoDepartment of Dermatology, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China.
Yuzhou CaiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Kunming Medical University, Yunnan, 650032, China.
Yu-Ye LiDepartment of Dermatology, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China. yyeli2000@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), have shown significant global increases in burden, particularly among older adults, with wide regional, gender, and socio-demographic disparities. However, no previous study has comprehensively analyzed these trends using integrated multi-model approaches. A comprehensive analysis of global non-melanoma skin cancer (NMSC) data from 1990 to 2021 was performed, including trend analysis, frontier analysis, and decomposition analysis to compare the burden of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) across regions, genders, and socio-demographic groups. Temporal trends in incidence, prevalence, and disability-adjusted life years (DALYs) were identified using epidemiological decomposition techniques. To forecast future disease burden from 2022 to 2050, eight machine learning models (Prophet, ARIMA, TBATS, ElasticNet, ETS, VAR, HoltWinters, and Theta) were applied, and the most optimal predictive models for BCC and SCC were selected based on performance metrics. From 1990 to 2021, the global burden of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) among older adults increased substantially. The incidence of BCC rose by 291.85%, with an age-standardized rate (ASR) increase of 62.79%, while SCC incidence increased by 322.77%, with a 67.42% rise in ASR. High Socio-Demographic Index (SDI) regions showed the largest ASR increases for BCC (102.73%) and SCC (107.31%), whereas low SDI regions demonstrated more modest changes or declines (BCC: - 2.86%, SCC: - 3.08%). Gender disparities were observed, with males accounting for 56.47% of SCC cases globally. Decomposition analysis revealed that population growth was the primary driver of increased NMSC burden, contributing 62.52-83.92% of the rise in incidence and DALYs, while epidemiological changes accounted for up to 52.2% in high SDI regions. Frontier analysis highlighted significant regional disparities, with high SDI regions, such as North America, exhibiting the highest age-standardized incidence rates for BCC (2,923.22 per 100,000) and SCC (1,805.33 per 100,000), whereas low SDI regions, like sub-Saharan Africa, showed minimal burdens near frontier values. Finally, disease burden forecasting for 2022 to 2050 using machine learning models predicted a slight decrease in the incidence rates of BCC (from 314.00 to 308.73 per 100,000) and SCC (from 157.67 to 148.16 per 100,000). Disability-adjusted life years (DALYs) are projected to decline for SCC (79.32 to 75.20 per 100,000) but increase slightly for BCC (0.136 to 0.151 per 100,000). These projections underscore the need for tailored strategies to address the growing burden of NMSC. The growing global burden of NMSCs, particularly in high SDI regions and among older adults, underscores the urgent need for tailored prevention, resource allocation, and management strategies. Machine learning-based approaches provide robust insights into global trends and future challenges for BCC and SCC.

Indexed as

Basal Cell CarcinomaCarcinoma, Squamous CellMachine LearningSkin NeoplasmsAgedAged, 80 and overDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseGlobal HealthHumansIncidenceMaleMiddle AgedPrevalenceBasal cell carcinomaEpidemiological trendsForecastingGlobal burdenMachine learningNon-melanoma skin cancerSocio-demographic disparitiesSquamous cell carcinoma

Identifiers

PMID40312476
PMCPMC12045994

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.